Rafanan J, Ghani N, Kazemeini S, Nadeem-Tariq A, Shih R, Vida T
Int J Mol Sci. 2025; 26(3).
PMID: 39940686
PMC: 11817476.
DOI: 10.3390/ijms26030917.
Roth P, Capper D, Calabrese E, Halasz L, Jakola A
Neurooncol Pract. 2025; 12(Suppl 1):i29-i37.
PMID: 39776528
PMC: 11703365.
DOI: 10.1093/nop/npae100.
Choate K, Pratt E, Jennings M, Winn R, Mann P
Biology (Basel). 2024; 13(11).
PMID: 39596840
PMC: 11592129.
DOI: 10.3390/biology13110885.
Ippen F, Hielscher T, Friedel D, Gobel K, Reuss D, Herold-Mende C
Neuro Oncol. 2024; 27(3):743-754.
PMID: 39530475
PMC: 11889711.
DOI: 10.1093/neuonc/noae238.
Lim-Fat M, Bennett J, Ostrom Q, Touat M, Franceschi E, Schulte J
Neuro Oncol. 2024; 27(1):13-32.
PMID: 39441704
PMC: 11726256.
DOI: 10.1093/neuonc/noae186.
Absolute Metabolite Quantification in Individuals with Glioma and Healthy Individuals Using Whole-Brain Three-dimensional MR Spectroscopic and Echo-planar Time-resolved Imaging.
Baboli M, Wang F, Dong Z, Dietrich J, Uhlmann E, Batchelor T
Radiology. 2024; 312(3):e232401.
PMID: 39315894
PMC: 11449233.
DOI: 10.1148/radiol.232401.
Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma.
Richardson T, Walker J, Hambardzumyan D, Brem S, Hatanpaa K, Viapiano M
Acta Neuropathol. 2024; 148(1):5.
PMID: 39012509
PMC: 11252228.
DOI: 10.1007/s00401-024-02761-7.
The 2021 World Health Organization Central Nervous System Tumor Classification: The Spectrum of Diffuse Gliomas.
Gue R, Lakhani D
Biomedicines. 2024; 12(6).
PMID: 38927556
PMC: 11202067.
DOI: 10.3390/biomedicines12061349.
IDH inhibition in gliomas: from preclinical models to clinical trials.
Ruda R, Horbinski C, van den Bent M, Preusser M, Soffietti R
Nat Rev Neurol. 2024; 20(7):395-407.
PMID: 38760442
DOI: 10.1038/s41582-024-00967-7.
Glioma.
Weller M, Wen P, Chang S, Dirven L, Lim M, Monje M
Nat Rev Dis Primers. 2024; 10(1):33.
PMID: 38724526
DOI: 10.1038/s41572-024-00516-y.
Diagnostic Challenges during Inflammation and Cancer: Current Biomarkers and Future Perspectives in Navigating through the Minefield of Reactive versus Dysplastic and Cancerous Lesions in the Digestive System.
Pateras I, Igea A, Nikas I, Leventakou D, Koufopoulos N, Ieronimaki A
Int J Mol Sci. 2024; 25(2).
PMID: 38279253
PMC: 10816510.
DOI: 10.3390/ijms25021251.
Motor dysfunction as a primary symptom predicts poor outcome: multicenter study of glioma symptoms.
Kivioja T, Posti J, Sipila J, Rauhala M, Frantzen J, Gardberg M
Front Oncol. 2024; 13:1305725.
PMID: 38239655
PMC: 10794640.
DOI: 10.3389/fonc.2023.1305725.
Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma.
Weller M, Felsberg J, Hentschel B, Gramatzki D, Kubon N, Wolter M
Acta Neuropathol. 2024; 147(1):11.
PMID: 38183430
PMC: 10771615.
DOI: 10.1007/s00401-023-02662-1.
Methylation Profiling Identifies Stability of Isocitrate Dehydrogenase Mutation Over Time.
Voisin M, Gui C, Patil V, Gao A, Zadeh G
Can J Neurol Sci. 2023; 51(3):362-368.
PMID: 37434550
PMC: 11892112.
DOI: 10.1017/cjn.2023.253.
Proinflammatory Macrophage Activation by the Polysialic Acid-Siglec-16 Axis Is Linked to Increased Survival of Patients with Glioblastoma.
Thiesler H, Gretenkort L, Hoffmeister L, Albers I, Ohlmeier L, Rockle I
Clin Cancer Res. 2023; 29(12):2266-2279.
PMID: 37058255
PMC: 10330235.
DOI: 10.1158/1078-0432.CCR-22-1488.
Pediatric brain tumors: A neuropathologist's approach to the integrated diagnosis.
Viaene A
Front Pediatr. 2023; 11:1143363.
PMID: 36969278
PMC: 10030595.
DOI: 10.3389/fped.2023.1143363.
Characterization of an IDH1 R132H Rabbit Monoclonal Antibody, MRQ-67, and Its Applications in the Identification of Diffuse Gliomas.
Copaciu R, Rashidian J, Lloyd J, Yahyabeik A, McClure J, Cummings K
Antibodies (Basel). 2023; 12(1).
PMID: 36810519
PMC: 9944093.
DOI: 10.3390/antib12010014.
A high-density 3-dimensional culture model of human glioblastoma for rapid screening of therapeutic resistance.
Brown J, Zaben M, Ormonde C, Sharouf F, Spencer R, Bhatt H
Biochem Pharmacol. 2023; 208:115410.
PMID: 36632958
PMC: 10840506.
DOI: 10.1016/j.bcp.2023.115410.
Towards a single-assay approach: a combined DNA/RNA sequencing panel eliminates diagnostic redundancy and detects clinically-relevant fusions in neuropathology.
Slocum C, Park H, Baek I, Catalano J, Wells M, Liechty B
Acta Neuropathol Commun. 2022; 10(1):167.
PMID: 36397144
PMC: 9670552.
DOI: 10.1186/s40478-022-01466-w.
Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET.
Wollring M, Werner J, Bauer E, Tscherpel C, Ceccon G, Lohmann P
Neuro Oncol. 2022; 25(5):984-994.
PMID: 36215231
PMC: 10158105.
DOI: 10.1093/neuonc/noac229.